Celldex Therapeutics (CLDX) Current Leases (2019 - 2026)

Celldex Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Current Leases fell 2.27% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 2.27% YoY), while the FY2025 annual figure was $1.6 million, up 6.89% from the prior year.
• Current Leases for Q1 2026 stood at $1.5 million, down from $1.6 million in the prior quarter.
• The five-year high for Current Leases was $1.8 million in Q1 2022, with the low at $1.4 million in Q3 2024.
• The 5-year median for Current Leases is $1.5 million (2023), against an average of $1.5 million.
• Peak annual rise in Current Leases reached 31.34% in 2022, while the deepest fall reached 17.24% in 2022.
• Celldex Therapeutics' Current Leases stood at $1.4 million in 2022, then grew by 11.7% to $1.6 million in 2023, then retreated by 10.04% to $1.5 million in 2024, then increased by 6.89% to $1.6 million in 2025, then dropped by 5.61% to $1.5 million in 2026.
• Business Quant data shows CLDX's Current Leases at $1.5 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.